DNA topoisomerase inhibitors - Pipeline Insight, 2022
This report can be delivered to the clients within 24 Hours
DelveInsight’s, “DNA topoisomerase inhibitors - Pipeline Insight, 2022” report provides comprehensive insights about 20+ companies and 20+ pipeline drugs in DNA topoisomerase inhibitors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
DNA topoisomerase inhibitors: Overview
Topoisomerases are essential and ubiquitous enzymes that regulate DNA topology by making temporary single- (type I) or double-strand DNA breaks (type II) [1], [2]. The DNA double helix needs to be unwound for processes such as DNA replication or transcription to take place, giving rise to the accumulation of positive supercoils ahead of transcription bubbles and replication forks, and negative supercoils or pre-catenanes behind. Topoisomerases relax supercoiled DNA and decatenate DNA to allow DNA transcription and replication to take place and are essential for genome stability
Function - DNA topoisomerases are enzymes that catalyze the alteration of DNA topology with transiently induced DNA strand breakage, essential for DNA replication. Topoisomerases are validated cancer chemotherapy targets. Anticancer agents targeting Topoisomerase I and II have been in clinical use and proven to be highly effective, though with significant side effects. There are tremendous efforts to develop new generation of topoisomerase inhibitors.
DNA topoisomerase inhibitors - Topoisomerase inhibitors are chemical compounds that block the action of topoisomerases, which are broken into two broad subtypes: type I topoisomerases (TopI) and type II topoisomerases (TopII). Topoisomerase plays important roles in cellular reproduction and DNA organization, as they mediate the cleavage of single and double stranded DNA to relax supercoils, untangle catenanes, and condense chromosomes in eukaryotic cells. Topoisomerase inhibitors influence these essential cellular processes. Some topoisomerase inhibitors prevent topoisomerases from performing DNA strand breaks while others, deemed topoisomerase poisons, associate with topoisomerase-DNA complexes and prevent the re-ligation step of the topoisomerase mechanism. These topoisomerase-DNA-inhibitor complexes are cytotoxic agents, as the un-repaired single and double stranded DNA breaks that they cause can lead to apoptosis and cell death. Because of this ability to induce apoptosis, topoisomerase inhibitors have gained interest as therapeutics against infectious and cancerous cells.
DNA topoisomerase inhibitors Emerging Drugs Chapters
This segment of the DNA topoisomerase inhibitors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
DNA topoisomerase inhibitors Emerging Drugs
Further product details are provided in the report……..
DNA topoisomerase inhibitors: Therapeutic Assessment
This segment of the report provides insights about the different DNA topoisomerase inhibitors drugs segregated based on following parameters that define the scope of the report, such as:
DNA topoisomerase inhibitors: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses DNA topoisomerase inhibitors therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging DNA topoisomerase inhibitors drugs.
Report Highlights
Current Scenario and Emerging Therapies:
DelveInsight’s, “DNA topoisomerase inhibitors - Pipeline Insight, 2022” report provides comprehensive insights about 20+ companies and 20+ pipeline drugs in DNA topoisomerase inhibitors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
DNA topoisomerase inhibitors: Overview
Topoisomerases are essential and ubiquitous enzymes that regulate DNA topology by making temporary single- (type I) or double-strand DNA breaks (type II) [1], [2]. The DNA double helix needs to be unwound for processes such as DNA replication or transcription to take place, giving rise to the accumulation of positive supercoils ahead of transcription bubbles and replication forks, and negative supercoils or pre-catenanes behind. Topoisomerases relax supercoiled DNA and decatenate DNA to allow DNA transcription and replication to take place and are essential for genome stability
Function - DNA topoisomerases are enzymes that catalyze the alteration of DNA topology with transiently induced DNA strand breakage, essential for DNA replication. Topoisomerases are validated cancer chemotherapy targets. Anticancer agents targeting Topoisomerase I and II have been in clinical use and proven to be highly effective, though with significant side effects. There are tremendous efforts to develop new generation of topoisomerase inhibitors.
DNA topoisomerase inhibitors - Topoisomerase inhibitors are chemical compounds that block the action of topoisomerases, which are broken into two broad subtypes: type I topoisomerases (TopI) and type II topoisomerases (TopII). Topoisomerase plays important roles in cellular reproduction and DNA organization, as they mediate the cleavage of single and double stranded DNA to relax supercoils, untangle catenanes, and condense chromosomes in eukaryotic cells. Topoisomerase inhibitors influence these essential cellular processes. Some topoisomerase inhibitors prevent topoisomerases from performing DNA strand breaks while others, deemed topoisomerase poisons, associate with topoisomerase-DNA complexes and prevent the re-ligation step of the topoisomerase mechanism. These topoisomerase-DNA-inhibitor complexes are cytotoxic agents, as the un-repaired single and double stranded DNA breaks that they cause can lead to apoptosis and cell death. Because of this ability to induce apoptosis, topoisomerase inhibitors have gained interest as therapeutics against infectious and cancerous cells.
DNA topoisomerase inhibitors Emerging Drugs Chapters
This segment of the DNA topoisomerase inhibitors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
DNA topoisomerase inhibitors Emerging Drugs
- DNV3837: Deinove
- CXD 201: Celleron Therapeutics
Further product details are provided in the report……..
DNA topoisomerase inhibitors: Therapeutic Assessment
This segment of the report provides insights about the different DNA topoisomerase inhibitors drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players working on DNA topoisomerase inhibitors
- Phases
- Late-stage products (Phase III and
- Mid-stage products (Phase II and
- Early-stage products (Phase I/II and Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Infusion
- Intradermal
- Intramuscular
- Intranasal
- Intravaginal
- Oral
- Parenteral
- Subcutaneous
- Topical.
- Molecule Type
- Vaccines
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Product Type
DNA topoisomerase inhibitors: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses DNA topoisomerase inhibitors therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging DNA topoisomerase inhibitors drugs.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence DNA topoisomerase inhibitors R&D. The therapies under development are focused on novel approaches for DNA topoisomerase inhibitors.
- DNA topoisomerase inhibitors Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Scenario and Emerging Therapies:
- How many companies are developing DNA topoisomerase inhibitors drugs?
- How many DNA topoisomerase inhibitors drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for DNA topoisomerase inhibitors?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the DNA topoisomerase inhibitors therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for DNA topoisomerase inhibitors and their status?
- What are the key designations that have been granted to the emerging drugs?
- Deinove
- Celleron Therapeutics
- BioNumerik Pharmaceuticals
- Shasqi
- Mundipharma
- Oasmia Pharmaceutical
- Gibson Oncology
- GlaxoSmithKline
- Fujifilm Pharmaceuticals USA
- Ascelia Pharma
- Nektar Therapeutics
- Luye Pharma
- Targeted Therapy Technologies
- Athenex
- Cao Pharmaceuticals
- Intezyne
- RedxPharma
- DNV3837
- CXD 201
- Cositecan
- SQ 3370
- Etoposide toniribate
- Research programme: cancer therapeutics
- Indotecan
- Gepotidacin
- Topotecan liposomal
- Irinotecan oral
- Etirinotecan pegol
- Irinotecan hydrochloride liposomal
- Episcleral topotecan
- Encequidar/topotecan
- CZ 48
- IT 141
Introduction
Executive Summary
DNA topoisomerase inhibitors: Overview
Structure
Mechanism of Action
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
DNA topoisomerase inhibitors – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
DNA topoisomerase inhibitors companies’ collaborations, Licensing, Acquisition -Deal Value Trends
DNA topoisomerase inhibitors Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Pre-registration)
Comparative Analysis
Drug name: Company name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
DNV3837 : Deinove
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Comparative Analysis
CXD 201: Celleron Therapeutics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Pre-clinical and Discovery Stage Products
Comparative Analysis
Drug name: Company name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
DNA topoisomerase inhibitors Key Companies
DNA topoisomerase inhibitors Key Products
DNA topoisomerase inhibitors- Unmet Needs
DNA topoisomerase inhibitors- Market Drivers and Barriers
DNA topoisomerase inhibitors- Future Perspectives and Conclusion
DNA topoisomerase inhibitors Analyst Views
DNA topoisomerase inhibitors Key Companies
Appendix
Executive Summary
DNA topoisomerase inhibitors: Overview
Structure
Mechanism of Action
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
DNA topoisomerase inhibitors – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
DNA topoisomerase inhibitors companies’ collaborations, Licensing, Acquisition -Deal Value Trends
DNA topoisomerase inhibitors Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Pre-registration)
Comparative Analysis
Drug name: Company name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
DNV3837 : Deinove
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Comparative Analysis
CXD 201: Celleron Therapeutics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Pre-clinical and Discovery Stage Products
Comparative Analysis
Drug name: Company name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
DNA topoisomerase inhibitors Key Companies
DNA topoisomerase inhibitors Key Products
DNA topoisomerase inhibitors- Unmet Needs
DNA topoisomerase inhibitors- Market Drivers and Barriers
DNA topoisomerase inhibitors- Future Perspectives and Conclusion
DNA topoisomerase inhibitors Analyst Views
DNA topoisomerase inhibitors Key Companies
Appendix
LIST OF TABLES
Table 1 Total Products for DNA topoisomerase inhibitors
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
Table 1 Total Products for DNA topoisomerase inhibitors
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
LIST OF FIGURES
Figure 1 Total Products for DNA topoisomerase inhibitors
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Figure 1 Total Products for DNA topoisomerase inhibitors
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
